Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
In vivo inhibition of tumour growth by dexamethasone in murine osteosarcomas
Autore:
Kudawara, I; Ueda, T; Yoshikawa, H; Miyama, T; Yamamoto, T; Nishizawa, Y;
Indirizzi:
Osaka Natl Hosp, Dept Orthopaed Surg, Chuo Ku, Osaka 5400006, Japan Osaka Natl Hosp Osaka Japan 5400006 Surg, Chuo Ku, Osaka 5400006, Japan Osaka Univ, Grad Sch Sci, Dept Orthopaed Surg, Suita, Osaka 5650871, JapanOsaka Univ Suita Osaka Japan 5650871 ed Surg, Suita, Osaka 5650871, Japan Osaka Med Ctr Canc & Cardiovasc Dis, Dept Pathol, Osaka 5378511, Japan Osaka Med Ctr Canc & Cardiovasc Dis Osaka Japan 5378511 a 5378511, Japan Osaka Univ, Grad Sch Pharmaceut Sci, Dept Clin & Expt Pathophysiol, Suita,Osaka 5650871, Japan Osaka Univ Suita Osaka Japan 5650871 ophysiol, Suita,Osaka 5650871, Japan
Titolo Testata:
EUROPEAN JOURNAL OF CANCER
fascicolo: 13, volume: 37, anno: 2001,
pagine: 1703 - 1708
SICI:
0959-8049(200109)37:13<1703:IVIOTG>2.0.ZU;2-H
Fonte:
ISI
Lingua:
ENG
Soggetto:
GLUCOCORTICOID RECEPTOR; NATURAL-KILLER; COMBINATION CHEMOTHERAPY; OSTEOGENIC-SARCOMA; LEUKEMIC-CELLS; ONCOLOGY-GROUP; DIFFERENTIATION; CORTICOSTEROIDS; PROLIFERATION; INTERFERON;
Keywords:
osteosarcoma; dexamethasone; glucocorticoid; mifepristone; glucocorticoid receptor;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
31
Recensione:
Indirizzi per estratti:
Indirizzo: Kudawara, I Osaka Natl Hosp, Dept Orthopaed Surg, Chuo Ku, 2-1-14 Hoenzaka, Osaka 5400006, Japan Osaka Natl Hosp 2-1-14 Hoenzaka Osaka Japan 540000606, Japan
Citazione:
I. Kudawara et al., "In vivo inhibition of tumour growth by dexamethasone in murine osteosarcomas", EUR J CANC, 37(13), 2001, pp. 1703-1708

Abstract

This study was performed to determine whether glucocorticoid (GC) is an effective inhibitor of tumour growth in murine osteosarcoma (OS) in vivo. Theeffects of dexamethasone (DEX) on the growth of this tumour were studied in male C3H/He mice. The animals received a dose of 1.25 or 5 mug/g of DEX in 0.1 ml of steroid solution daily intraperitoneally (i.p.) for 14 days. Ineach DEX-treated group, significant inhibition of the tumour growth curve was seen in a dose- dependent manner compared with the control group (P <0.0001). The percentage of proliferative cell nuclear antigen (PCNA)-positivecells was 22.7% in the 5 mug/g DEX treatment group compared with 67.6% in the control group (P=0.009). Furthermore, mifepristone, a GC receptor antagonist, blocked the inhibition of tumour growth induced by DEX. In the control group, tumour cells showed positive reactivity for nuclear glucocorticoid receptors (GR) by immunohistochemistry. The results of this study indicate that tumour growth inhibition by DEX in murine osteosarcoma may be via GR. (C) 2001 Elsevier Science Ltd. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 23/01/20 alle ore 03:33:35